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Introduction
TTFields are intermediate frequency (100–300 kHz) alternating fields, which disrupt cancer growth. The 
treatment has proven effective against glioblastoma (GBM) (Stupp et al 2012, 2017, Mun et al 2018) and is 
currently being tried for multiple other solid tumors (Mun et al 2018). TTFields are induced by two current 
sources each connected a pair of 3  ×  3 transducer arrays placed on the patient’s scalp (Trusheim et al 2017). 
The sources are activated in sequence using a 50% activation cycle of 2 s total duration, i.e. each transducer pair 
is activated for 1 s followed by a 1 s ‘off’ period. When one pair is active the other is inactive and vice versa, i.e. 
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Abstract
Tumor treating fields (TTFields) are increasingly used to treat newly diagnosed and recurrent 
glioblastoma (GBM). Recently, the authors proposed a new and comprehensive method for efficacy 
estimation based on singular value decomposition of the sequential field distributions. The method 
accounts for all efficacy parameters known to affect anti-cancer efficacy of TTFields, i.e. intensity, 
exposure time, and spatial field correlation. In this paper, we describe a further development, which 
enables individual optimization of the TTFields activation cycle. The method calculates the optimal 
device settings to obtain a desired average field intensity in the tumor, while minimizing unwanted 
field correlation.
Finite element (FE) methods were used to estimate the electrical field distribution in the head. 
The computational head model was based on MRI data from a GBM patient. Sequential field vectors 
were post-processed using singular value decomposition. A linear transformation was applied to the 
resulting field matrix to reduce fractional anisotropy (FA) of the principal field components in the 
tumor.
Results were computed for four realistic transducer array layouts. The optimization method 
significantly reduced FA and maintained the average field intensity in the tumor. The algorithm 
produced linear gain factors to be applied to the transducer array pairs producing the sequential 
fields. FA minimization was associated with an increase in total current delivered through the head 
during a activation cycle. Minimized FA can be obtained for an unchanged total current level, albeit 
with a reduction in average field intensity.
We present an algorithm for optimization of the TTFields activation cycle settings. The method 
can be used to minimize the spatial correlation between sequential TTFields, while adjusting the total 
current level and mean field intensity to a desired level. Future studies are needed to validate clinical 
impact and assess sensitivity towards model parameters.
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each pair is activated in a ‘square waveform’ pattern. During activation, the individual sources deliver sinusoidal 
field waveforms at 200 kHz (for GBM). The induced fields are applied in approximately orthogonal directions 
based on a perpendicular layout of the two array pairs. The therapeutic efficacy of TTFields depends on the 
induced field intensity as well as the exposure time and the direction of the sequential fields relative to each 
other (Kirson et al 2004). Specifically, the growth rate of cancer cell cultures has been shown to decrease with 
increasing intensity and exposure-time of TTFields (Kirson et al 2004). Similarly, a recent study showed that 
the overall survival of GBM patients treated with TTFields correlated positively with the cumulative TTFields 
exposure, calculated as the average field intensity over time (Urman et al 2017). TTFields has also been shown 
to preferentially disrupt mitosis for cells dividing in the direction of the applied field (Kirson et al 2004, Wenger 
et al 2015a). This latter notion is supported by the in vivo results showing that two sequential and orthogonal 
fields increase the therapeutic efficacy by  ≈20% compared to one constantly active field (Kirson et al 2007). This 
illustrates that the use of multiple field directions enables the distribution of the anti-cancer effect more evenly 
among cells dividing in different (random) directions thereby reducing the average tendency to differentially 
inhibit cells dividing in particular directions. Correspondingly, clinical TTFields therapy (Optune®, Novocure, 
Ltd.) uses two pairs of transducer arrays activated in even 50% activation cycles, as explained above. The two 
corresponding fields cover two spatial directions and thereby target a larger fraction of cells compared to one 
field alone, although three linearly independent fields (ideally orthogonal and of equal magnitude) would 
be required to obtain an unbiased distribution. In a clinical treatment setting, the transducer array layout is 
planned to maximize the intensity of TTFields in the tumor (Trusheim et al 2017). However, in a recent study, 
we demonstrated that the complex anatomy and conductivity distribution of the head gives rise to considerable 
unwanted spatial correlation of the induced fields indexed as fractional anisotropy (FA). FA is extensively used 
in diffusion tensor imaging (Basser and Pierpaoli 2011). In the context of TTFields, it is calculated from the 
principal component magnitudes and measures the fractional deviation of the induced fields from the isotropic 
condition in which the sequential TTFields are perfectly orthogonal and have equal magnitude. FA generally 
takes values between zero and one, with higher values representing unwanted field correlation, i.e. the average 
field over an activation cycle will tend to have a directional preference of activity. Using the FA index, we have 
demonstrated considerable unwanted field correlation in the tumor region even for layouts planned to maximize 
treatment efficacy (Korshoej and Thielscher 2018). This means that although the array layouts were planned to 
induce orthogonal (i.e. uncorrelated) sequential fields, the actual induced fields were in fact highly correlated 
(figure 1) to each other. This problem has previously been ignored in TTFields treatment and computational 
studies of TTFields potentially compromising or reducing the therapeutic efficacy.
In this study, we propose a computational method, which optimizes the activation cycle settings of TTFields 
to minimize unwanted spatial field correlation in any local region of a computational volume conductor model. 
The optimization method is based on a linear transformation and can be used for any particular array layout, any 
number of active fields, and any choice of desired average field intensity in the tumor. We provide modeling data 
validating the method’s ability to decorrelate the induced fields for different layouts. The method may poten-
tially be used in future embodiments of the TTFields technology to optimize the treatment efficacy for individual 
cancer patients.
Methods
Model preparation and electrical field calculations
The head model was created from MRI data obtained from a patient with left-sided parietal GBM (figure 2(A)). 
Written consent was obtained from the patient. The head model was segmented into six tissue types, namely, 
skin, skull, cerebrospinal fluid (CSF), gray matter (GM), white matter (WM) and tumor. The configuration of 
TTFields was equivalent to the Optune® technology, which is used for clinical treatment. Four different array 
layouts were investigated (figure 2(C)). The distribution of the induced electric field was calculated using a finite 
element (FE) approximation of Laplace’s equation for the electric potential, ∇ · (σ∇ϕ) = 0 (Miranda et al 2014, 
Korshoej et al 2016, 2017a, 2017b,  Bomzon et al 2016, Lok et al 2017). This is valid at the low-to-intermediate 
frequencies of TTFields (e.g. 200 kHz), because the electromagnetic wavelength in the relevant tissues is much 
larger than the size of the head (Plonsey and Heppner 1967, Miranda et al 2014, Wenger et al 2015b). Furthermore, 
skin effect can be neglected at 200 kHz. The currents induced by TTFields are, therefore, mainly resistive (Ohmic) 
currents. Regarding the relationship between field frequency and cancer growth inhibition, we kindly refer the 
reader to Wenger et al (2015) and Kirson et al (2004). Finite element calculations were performed with SimNIBS 
(www.simnibs.org) (Windhoff et al 2013). We used Dirichlet boundary conditions with a fixed electric potential 
at each array (Saturnino et al 2015, Opitz et al 2015). Isotropic conductivity values were assumed for skin 
(0.25 S m−1), skull (0.010 S m−1) and CSF (1.625 S m−1) (Gabriel et al 2009, Korshoej et al 2016). For GM, 
WM and tumor tissues, we assumed anisotropic conductivity tensors inferred from diffusion MRI data (Tuch 
et al 2001, Korshoej et al 2016). The electric field was calculated as the numerical gradient of the potential. We 
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calculated the current density using Ohm’s law. The electric potentials, fields, and current densities were rescaled 
to obtain a peak-to-peak current amplitude of 1.8 A for each array pair. Further details about the head model 
generation and electric field calculation can be found in Korshoej et al (2016, 2017a, 2018) and Wenger et al 
(2018).
Estimation of average intensity and field correlation using singular value decomposition
For each finite element we defined the field matrixε with the transposed sequential field vectors Ei in each row:
ε =

ET1
...
ETn
  Rn×3. (1)
In addition, we defined the relative activation time αi of Ei as
0 < αi =
ti∑n
j=1 tj
< 1, (2)
where ti  0  is the ‘on-time’ of Ei during the activation-cycle (α1 = α2 = 12 for Optune®, i.e. a 50% activation 
cycle). In this context, it is important to appreciate, that the notion of activation cycle in this context refers to the 
!
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Figure 1. (A) and (C) Axial sections of the electric field distribution induced by the A/P and L/R array layouts, respectively. The 
field magnitude is indicated by the color bar (0–350 V m−1) and a black line outlines the tumor. (B) Enlarged schematic view of the 
superimposed field vectors induced by the A/P (green) and L/R (blue) array layouts in a small region (five elements) of the tumor. 
The fields in each element display significant spatial correlation.
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Figure 2. Head model used for finite element calculation of the electric field distribution. (A) Gadolinium enhanced T1 MRI data 
showing the patient’s left parietal GBM. (B) Tetrahedral volume mesh reconstruction of MRI data segmented into different tissues. 
(C) Surface view of four different array layouts tested. The figure is adapted from Korshoej et al (2018).
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pattern of field source activation and not the duty-cycle of the 200 kHz sinusoidal signal induced by the source. 
We used ARn×n as the diagonal activation time matrix with entries aii =
√
αi  and define an ‘activation-time-
weighted’ electric field matrix
P = AεRn×3. (3)
We performed a singular value decomposition (SVD) of P to obtain a new representation of P defined by up to 
three principal components, i.e. orthonormal (uncorrelated) basis vectors collected in the matrix WR3×3:
P = UΣWTRn×3. (4)
The matrix ΣRn×3 contains the singular values σk, k  3, i.e. the magnitudes of the principal components.
We defined the average intensity of TTFields in each element as the Frobenius norm of P, i.e.
Eavr = ‖P‖F =
Ã
n∑
i=1
αiE
2
i =
Ã
3∑
k=1
σ2k . (5)
Thus, the average field was calculated as the square root of the activation-time weighted energy contributions 
from each field. The field correlation was estimated as the fractional anisotropy (FA) (Basser and Pierpaoli 2011), 
i.e.
FA =
»
1/2
»
(σ1 − σ2)2 + (σ2 − σ3)2 + (σ3 − σ1)2√
σ21 + σ
2
2 + σ
2
3
. (6)
FA estimates the fractional deviation of P from the isotropic condition with orthogonal fields of equal intensity. 
In situations with  <3 singular values the missing values were defined to be zero.
For a more detailed discussion of the above derivations and definitions, the reader is kindly referred to Kor-
shoej and Thielscher (2018). Figure 3 shows a schematic illustration of the calculation steps.
Optimizing the activation cycle of TTFields to minimize the fractional anisotropy
The principle component approach allows for optimization of the activation cycle such that FA can be minimized 
at a predefined average intensity for any array layout and in any region of interest. This can be done by applying 
the following linear transformation to P:
Q = UsInx3Σ
+UTRnxn. (7)
Here s > 0 is the desired isotropic singular value, Inx3Rnx3 is the truncated identity matrix and Σ+R3xn 
the pseudoinverse of Σ. In the following, we will refer to Q as the optimization matrix and we note that Q is 
symmetric. We see that the transformed field matrix G is given by
G = QP = UsInx3Σ
+UTUΣWT = UsInx3W
T , (8)
which is clearly isotropic with two non-zero singular values equal to s  as desired. Furthermore, 
GT = PTQT = εTAQT, so we may think of the column vectors of GT  as linear combinations of the original 
field vectors, in which the weighting factors defined by the entries in AQT  tell us how each field should be scaled 
to obtain an average distribution with minimum FA, i.e. equal singular values. To see this we define g j to be the 
j th row vector of G and thus gTj  is the j th column vector of G
T . Then, gTj =
∑n
i=1 qjiaiiEi and as expected we see 
that the scale factors qjiaii of each field Ei depend on both the corresponding activation time and the entries 
of the transformation matrix Q. Since the field vectors scale linearly with current, the j th row vector qj of Q 
may be considered a vector of relative gain factors qji applied in the j th activation period of the electrode pair 
inducing the corresponding field. This gain may be considered a scale factor for aii (activation time) or for the 
induced electric current, i.e. reduced anisotropy may be obtained by scaling current impressed by either layout 
or by scaling their relative activation times. To demonstrate how this linear transformation is able to significantly 
reduce unwanted FA of the time-weighted field distributions, we first need to define the region of interest (ROI) 
to which the optimization is applied. For a ROI comprising the finite elements k = 1, . . . ,m we define the average 
optimization matrix Qˆ as the median of optimization matrices Qk of all m elements in the ROI weighted by the 
relative volumes vk . If we consider the entries of Qˆ as containing scale factors for the induced electric current 
density, then the field distribution of the optimized (on average) activation cycle is given by G = QˆP for each 
element, because the electric field depends linearly on the current density.
Results
In the following, we will provide examples of activation cycle optimization using four different array layouts. In 
addition, we will choose the desired isotropic singular value s  so that Eavr  is maintained, i.e. we seek to derive scale 
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factors for current (or activation cycle period) settings of the TTFields device, which maintain the same average 
intensity, albeit with minimized FA in the tumor region. The objective is to distribute the energy isotropically 
in the span of the induced field vectors (rather than across all three dimensions of physical space), since we are 
using only two array layouts in accordance with the standard TTFields application. This corresponds to the best 
achievable activation cycle optimization possible with the number of active transducer arrays (i.e. fields). To 
achieve this we will set s =
…∑3
k=1
σ2
k
rank(E) =
Eavr√
rank(E) , so that the average intensity Eavr  is maintained after activation 
cycle optimization. The potential impact of the optimization procedure is illustrated in figure 4, which shows 
a scatter plot of the singular values in each element of the field distribution in the tumor and the peritumoral 
regions before and after activation cycle optimization. The results were based on the field distribution induced 
by Layout 1 using standard current settings (1800 mA peak-to-peak) and relative activation times α1 = α2 =
1
2. 
The figure confirms that the optimization procedure was able to reduce the difference between minimum and 
maximum singular values and hence reduce the FA in the ROI.
Figure 5 shows the cumulative distribution functions of Eavr  (figures 5(A) and (C)) and FA (figures 5(B) and 
(D)) for four different layouts. Results are shown both before (solid) and after (stippled) activation cycle optim-
ization. The optimization procedure maintains the Eavr  distributions largely unaffected, while FA is reduced for 
all layouts. FA was particularly high for Layout 1, which also produced the highest median Eavr, and for this layout 
the optimization resulted in a pronounced reduction of FA. Thus the procedure was able to reduce FA and main-
tain mean intensity for all layouts, as expected, and the extent of FA reduction was higher for Layout 1, which had 
the most significant initial anisotropy.
The findings above are further illustrated in table 1, which gives the relative changes in the area under the 
curve (AUC) values for the distribution functions shown in figure 5 for all layouts and regions of interest. AUC 
was nearly unaffected (1.2%–2.9%) for Eavr in both the tumor and the peritumoral region, while the corre-
sponding values for FA were considerably reduced (1.7%–43%).
The distribution of scale factors contained in the optimization matrix Qk is shown in figure 6, using 
Layouts 1 to 4 and the tumor as the ROI. The values of Qˆ for the tumor were QˆLayout 1 =
ñ
1.03 0.06
0.06 1.06
ô
, 
QˆLayout 2 =
ñ
1.02 −0.03
−0.03 1.06
ô
, QˆLayout 3 =
ñ
1.05 0.06
0.06 1.04
ô
, and QˆLayout 1 =
ñ
1.07 −0.15
−0.15 1.07
ô
. It is evident that the 
350
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Figure 3. (A) Axial sections of the topografical intensity distributions (0–350 V m−1) for the fields E1 and E2 induced by the L/R 
and A/P array layouts, respectively. (B) Topographical distributions of the minimum (σ2, bottom) and maximum (σ1, top) singular 
values (principal component magnitudes) after decomposition of the fields in each element. (C) Distributions of the mean intensity 
(Eavr, top) and spatial correlation (FA, bottom) calculated from the principal components of each element.
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Figure 4. Scatterplot of the minimum (σmin, 50–125 V m−1) and maximum (σmax, 50–250 V m−1) singular values for each finite 
element in the tumor region (A) and peritumoral region (B). Results are shown before (black) and after (magenta) activation cycle 
optimization. The optimization procedure reduces the FA in the ROIs, i.e. it reduces the difference between the corresponding 
singular values and moves the points closer to the isotropy line (solid black).
Figure 5. Cumulative distribution functions of Eavr  (A) and (C) and FA (B) and (D). Results are shown for the tumor region (A) and 
(B) and peritumoral region (C) and (D). Results for the standard field distributions are shown in solid, while the distributions of the 
optimized activation cycle are shown in stippled. The activation cycle optimization reduces FA and maintains Eavr  for all layouts.
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absolute row sums of Qˆ are  >  1, indicating that the induced current density (or activation cycle duration) 
required to maintain Eavr  and minimize FA is higher than the default current settings. This can potentially be 
addressed by considering a normalized optimization matrix Qˆnorm with entries qˆ
norm
ij =
qˆij∑rank(ε)
j=1 |qˆij|
, i.e. each 
entry normalized by the corresponding absolute row sum. This would ensure a constant total current density 
during each period of the activation cycle. The resulting field intensity would be lower than Eavr  while FA would 
remain unchanged and minimized since the induced fields have the same direction but are scaled by the same fac-
tor. Consequently, the optimization process can be designed to consider the desired total current density, average 
field intensity and minimized FA in order to obtain an appropriate balance between these parameters.
Discussion
We have described a new method to optimize the activation cycle of TTFields for any given layout. The method 
enables minimization of unwanted spatial correlation (FA) of sequentially induced TTFields while maintaining 
the average field intensity at a desired level in a region of interest, or alternatively maintaining the total impressed 
current density at a particular level. The approach is based on a linear transformation of the distribution of 
principal field components, as derived by the authors in a separate study. The post-processing procedure is applied 
to calculated sequential field distributions in a volume conductor model. In this study, we have demonstrated 
that the algorithm robustly minimizes FA while maintaining the average field intensity for four different layouts.
The optimization method produces a matrix of linear scale factors representing either (1) electrical cur-
rent gains applied to each sequential field during the activation cycle, or alternatively (2) scaling factors used to 
balance the duration of each period in the activation cycle. If the optimization matrix entries are interpreted as 
current gain factors, then the proposed method uses a balanced simultaneous activation of all array layouts to 
produce resulting field vectors, which on average are less spatially correlated in any small volume in a region of 
interest such as the tumor. This is contrary to the contemporary implementation TTFields, which uses strictly 
sequential fields. When the entries of the optimization matrix are interpreted as modifying factors for the acti-
vation cycle duration, the fields would still be applied sequentially, although each period would be scaled by the 
corresponding entry. When the optimization matrix is used to scale the current, the reduced FA and unchanged 
field intensity would imply a higher total current to be impressed by the system, compared to the default settings, 
which might potentially increase the risk of tissue heating. The user would therefore be required to personalize 
the activation cycle settings to obtain a desired balance between total current, average field and FA in the tumor. 
When the optimization matrix is used to scale the activation cycle periods, the induced peak current density 
Table 1. Relative change in AUC for Eavr  and FA in the tumor and peritumoral regions for Layouts 1 to 4.
Relative ∆AUCEavr  
tumor (%)
Relative ∆AUCFA 
tumor (%)
Relative ∆AUCEavr  
peritumor (%)
Relative ∆AUCFA 
peritumor (%)
Layout 1 1.20 −43.4 1.55 −38.4
Layout 2 1.46 −1.69 1.71 −6.9
Layout 3 1.52 −11.5 2.19 −13.4
Layout 4 2.93 −10.8 1.53 −15.8
Figure 6. Probability density distributions of entries in the symmetric average optimization matrix. Panel (A) represents the matrix 
entry Q1,1, panel (B) the identical diagonal entries Q1,2 and Q2,1, and panel (C) the entry Q2,2.
Phys. Med. Biol. 64 (2019) 04NT03 (9pp)
8A R Korshoej et al
would be constant, however, a potential complication might be that FA minimization would imply longer rela-
tive activation time of the weaker field, while the stronger field would have a shorter relative activation time. 
Despite the fact that the weaker field is active for longer periods, the difference in activation time may potentially 
affect the tendency to develop skin rash underneath the transducer arrays, which is one of the more commonly 
observed complications to TTFields treatment. Also, it is important to note that the proposed optimization 
approach may be affected by non-linearities in the relationship between the field intensity and the anti-tumor 
efficacy. Until now, the intensity/response relationship has only been properly characterized for the field-range 
between 60 and 240 V m−1 in vitro, in which the relationship is approximately linear (Kirson et al 2004). How-
ever, it is possible that there exists a lower threshold for anti-tumor activity (<60 V m−1), i.e. a field value below 
which no anti-tumor activity would be observed, which would imply that it would not be desirable to spend any 
time during the activation cycle at or below this level. Contrary, FA optimization would be more relevant in field 
ranges where the anti-tumor effect increases less than linear with increasing field strength. In those regimes, FA 
could potentially be reduced while largely maintaining the effectiveness of the array pair creating the peak field 
strengths. This could for instance be relevant if the anti-tumor activity would saturate at some higher field inten-
sity (e.g.  >240 V m−1). In conclusion, future studies are required to establish the dose/response relationship of 
TTFields more accurately and it is necessary to incorporate information about field intensity and correlation in 
such studies.
Limitations and future perspectives
A key ability of the proposed method is to reduce unwanted spatial field correlation, which is known to influence 
the extent of cancer cell damage in vitro. However, future studies are needed to validate the clinical importance 
of FA as it was recently done for field intensity (Urman et al 2017). In addition, it is necessary to characterize the 
independent correlation of each parameter with clinical outcome to be able to predict the expected treatment 
efficacy and produce accurate optimization algorithms. Also, it would be valuable to characterize the sensitivity 
of the FA and Eavr estimates towards variations in model parameters (e.g. tissue conductivity) and tumor 
characteristics (e.g. morphology and location). Finally, it would be highly interesting to investigate potential 
performance limitations of the optimization algorithm, e.g. cases with very high FA in the region of interest. This 
might potentially be observed in cases with very high conductivity in the tumor or its vicinity due to shunting 
effects that would expectedly cause a locally inhomogeneous field distribution (Korshoej et al 2017a).
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